Weekly paclitaxel in the treatment of recurrent ovarian carcinoma.
| Autor: | Byrd L; Cancer Research UK, Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK., Thistlethwaite FC, Clamp A, Ton C, Hasan J, Jayson GC |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | European journal of gynaecological oncology [Eur J Gynaecol Oncol] 2007; Vol. 28 (3), pp. 174-8. |
| Abstrakt: | Purpose: To study the effect of weekly paclitaxel in the treatment of recurrent ovarian and peritoneal carcinoma. Methods: A retrospective analysis of patients treated at Christie Cancer Centre between May 2003 and May 2005 was carried out. Results: Fortynine patients with recurrent ovarian and peritoneal carcinoma were treated. The mean duration of treatment was 11 weeks, with 27 (54%) patients receiving 12 or more treatments. The most frequent non-haematological toxicities reported were mild nausea, constipation, lethargy and neuropathy. Moderate anaemia was noted in 50% of patients. Radiological assessment by CT scanning showed that complete or partial responses were achieved in 28% of patients. CA125 response was demonstrated in 63% of patients. Median time to recurrence was 149 days and median survival was 359 days. Conclusion: This study provides evidence for the role of weekly paclitaxel in the treatment of recurrent ovarian and peritoneal carcinoma even in a drug-resistant setting following multiple lines of prior therapy. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|